{"id":464212,"date":"2021-03-24T09:03:23","date_gmt":"2021-03-24T13:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464212"},"modified":"2021-03-24T09:03:23","modified_gmt":"2021-03-24T13:03:23","slug":"axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/","title":{"rendered":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations"},"content":{"rendered":"
\n

SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) — AXIM\u00ae Biotechnologies, Inc.<\/u><\/a> (OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or \u201cthe Company\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company\u2019s manufacturing partner, Empowered Diagnostics<\/u><\/a>, has filed an Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA) for the approval to use ImmunoPass\u2122, the Company\u2019s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations.<\/p>\n

AXIM announced<\/u><\/a> earlier this month that it has completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the Company\u2019s test to measure participants\u2019 levels of COVID-19 neutralizing antibodies. AXIM worked with Empowered Diagnostics to compile these study results for inclusion in this EUA.<\/p>\n

John W. Huemoeller II, AXIM\u00ae Biotech CEO, commented: \u201cWith recent news that vaccines are expected to be available to all American adults by May, travel will likely pick back up shortly. This makes ImmunoPass even more relevant as neutralizing antibodies drop off at varying rates following vaccination. In order to slow the spread of the COVID-19 virus, we need to understand not only whether a person has been vaccinated but also whether their current levels of neutralizing antibodies are high enough for safe travel.\u201d<\/p>\n

\n About AXIM\u00ae Biotechnologies<\/strong>
\n
Founded in 2014, AXIM\u00ae Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM\u2019s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com<\/u><\/a>.<\/p>\n

\n About Empowered Diagnostics<\/strong>
\n
Empowered Diagnostics delivers innovative, best-in-class diagnostic tests backed by leading experts in healthcare and biotechnology. Our mission is to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests. Based in Pompano Beach, Florida, Empowered Diagnostics is one of the largest capacity manufacturers of rapid diagnostic solutions in the United States. For more information, please visit www.empdx.net<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
The statements made by Axim Biotechnologies Inc., in this press release may be \u201cforward-looking\u201d in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim\u2019s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company\u2019s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim\u2019s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim\u2019s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at\u00a0www.sec.gov<\/a><\/u>. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.<\/p>\n

\n CONTACT:<\/strong>
\n
\n Public Relations Contact:<\/strong>
\n
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com<\/u><\/a>
www.cmwmedia.com<\/u><\/a><\/p>\n

\n AXIM Corporate Contact Info:<\/strong>
\n
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
investors@aximbiotech.com
888-759-0844<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) — AXIM\u00ae Biotechnologies, Inc. (OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or \u201cthe Company\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company\u2019s manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA) for the approval to use ImmunoPass\u2122, the Company\u2019s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations. AXIM announced earlier this month that it has completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the Company\u2019s test to measure participants\u2019 levels of COVID-19 neutralizing … <\/p>\n

Continue reading “AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464212","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) — AXIM\u00ae Biotechnologies, Inc. (OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or \u201cthe Company\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company\u2019s manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA) for the approval to use ImmunoPass\u2122, the Company\u2019s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations. AXIM announced earlier this month that it has completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the Company\u2019s test to measure participants\u2019 levels of COVID-19 neutralizing … Continue reading "AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T13:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations\",\"datePublished\":\"2021-03-24T13:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/\"},\"wordCount\":784,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/\",\"name\":\"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=\",\"datePublished\":\"2021-03-24T13:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/","og_locale":"en_US","og_type":"article","og_title":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk","og_description":"SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) — AXIM\u00ae Biotechnologies, Inc. (OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or \u201cthe Company\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company\u2019s manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA) for the approval to use ImmunoPass\u2122, the Company\u2019s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations. AXIM announced earlier this month that it has completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the Company\u2019s test to measure participants\u2019 levels of COVID-19 neutralizing … Continue reading \"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T13:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations","datePublished":"2021-03-24T13:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/"},"wordCount":784,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/","name":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=","datePublished":"2021-03-24T13:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTM2NSM0MDg4ODE1IzIwMjM5OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization-with-fda-for-use-of-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-po\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AXIM\u00ae Biotechnologies\u2019 Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464212"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464212\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}